Vedolizumab gets edge in IBD head-to-head

But did the trial design skew results?

A head-to-head comparison of adalimumab and vedolizumab for the treatment of ulcerative colitis finds vedolizumab is superior for clinical remission and endoscopic improvement, but not in achieving corticosteroid remission.